Chronic Rhinosinusitis With Nasal Polyps

Infectious Disease·MeSH: Rhinosinusitis

Prevalence

12000.0 / 100K

Incidence

1000.0 / 100K/yr

12 drugs in development·6 companies·15 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
xhance	Paratek Pharmaceuticals, Inc. (PRTK)

Phase 3(5)

Drug	Company
itepekimab	Sanofi (SNY)
Itepekimab	Sanofi (SNY)
lunsekimig	Sanofi (SNY)
LY3650150	ELI LILLY & Co (LLY)
Mometasone furoate nasal spray	Sanofi (SNY)

Phase 2(4)

Drug	Company
Antiretroviral Therapy	ELI LILLY & Co (LLY)
lunsekimig	Sanofi (SNY)
verekitug	Upstream Bio, Inc. (UPB)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 4(2)

Drug	Company
CM326 injection	Crinetics Pharmaceuticals, Inc. (CRNX)
omalizumab	Sanofi (SNY)

BioSniper tracks 12 drugs in development for Chronic Rhinosinusitis With Nasal Polyps across 6 companies.

There are 15 clinical trials targeting Chronic Rhinosinusitis With Nasal Polyps tracked by BioSniper.

The estimated prevalence of Chronic Rhinosinusitis With Nasal Polyps is approximately 12000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.